AU3029889A - Stabilization of 13,14-dihydro-15-ketoprostaglandins - Google Patents

Stabilization of 13,14-dihydro-15-ketoprostaglandins

Info

Publication number
AU3029889A
AU3029889A AU30298/89A AU3029889A AU3029889A AU 3029889 A AU3029889 A AU 3029889A AU 30298/89 A AU30298/89 A AU 30298/89A AU 3029889 A AU3029889 A AU 3029889A AU 3029889 A AU3029889 A AU 3029889A
Authority
AU
Australia
Prior art keywords
dihydro
ketoprostaglandins
stabilization
compound selected
ketoprostaglandin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU30298/89A
Other versions
AU612791B2 (en
Inventor
Sachiko Kuno
Ryuji Ueno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ueno Seiyaku Oyo Kenkyujo KK
Original Assignee
Ueno Seiyaku Oyo Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo KK filed Critical Ueno Seiyaku Oyo Kenkyujo KK
Publication of AU3029889A publication Critical patent/AU3029889A/en
Application granted granted Critical
Publication of AU612791B2 publication Critical patent/AU612791B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A stabilized 13,14-dihydro-15-ketoprostaglandin composition comprising an intimate mixture of a) a therapeutically effective amount of at least one compound selected from 13,14-dihydro-15-ketoprostaglandins and b) at least one compound selected from pharmaceutically acceptable etherized cyclodextrins. d
AU30298/89A 1988-02-26 1989-02-23 Stabilization of 13,14-dihydro-15-ketoprostaglandins Ceased AU612791B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP63045622A JP2597629B2 (en) 1988-02-26 1988-02-26 Stabilization of 13,14-dihydro-15-ketoprostaglandins
JP63-45622 1988-02-26

Publications (2)

Publication Number Publication Date
AU3029889A true AU3029889A (en) 1989-08-31
AU612791B2 AU612791B2 (en) 1991-07-18

Family

ID=12724473

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30298/89A Ceased AU612791B2 (en) 1988-02-26 1989-02-23 Stabilization of 13,14-dihydro-15-ketoprostaglandins

Country Status (13)

Country Link
EP (1) EP0330511B1 (en)
JP (1) JP2597629B2 (en)
KR (1) KR970005170B1 (en)
AT (1) ATE79260T1 (en)
AU (1) AU612791B2 (en)
CA (1) CA1314483C (en)
DE (1) DE68902401T2 (en)
ES (1) ES2044087T3 (en)
GB (1) GB2216004A (en)
GR (1) GR3005933T3 (en)
NZ (1) NZ228111A (en)
OA (1) OA09236A (en)
ZA (1) ZA891410B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
ES2052735T3 (en) * 1987-09-18 1994-07-16 R Tech Ueno Ltd A METHOD FOR PRODUCING AN EYE HYPOTENSION AGENT.
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
ATE101342T1 (en) * 1988-09-06 1994-02-15 Kabi Pharmacia Ab PROSTAGLAND INDIVIDUALS FOR THE TREATMENT OF GREEN STAR OR OCULAR HYPERTENSION.
ATE111736T1 (en) * 1988-10-01 1994-10-15 R Tech Ueno Ltd OCULAR HYPOTENSIVE REMEDIES.
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
ATE122563T1 (en) * 1989-07-27 1995-06-15 Ueno Seiyaku Oyo Kenkyujo Kk USE OF 15-KETO-PROSTONE ACID DERIVATIVES FOR PRODUCING A MEDICATION FOR IMPROVING THE EXCRETION OF POTASSIUM ION.
CA2022372C (en) * 1989-08-09 2000-05-02 Ryuji Ueno Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivatives
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
TW224942B (en) * 1990-04-04 1994-06-11 Adka Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
DE69213057T2 (en) * 1991-03-14 1997-01-09 Ueno Seiyaku Oyo Kenkyujo Kk Stimulation of wound healing with 15-keto prostaglandin compounds
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6169111B1 (en) 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
CA2502439C (en) 2002-10-23 2011-11-22 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US20080139652A1 (en) 2003-11-07 2008-06-12 Yusuke Sakai Pharmaceutical Composition Containing Prostaglandin
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910525A (en) * 1982-06-21 1984-01-20 Teisan Seiyaku Kk Stabilized composition of prostaglandin e
JPH0819004B2 (en) * 1986-12-26 1996-02-28 日清製粉株式会社 Sustained-release pharmaceutical preparation
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
ES2038289T3 (en) 1987-05-15 1993-07-16 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo USE OF 15-CETO-PGES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO INCREASE BODY TEMPERATURE.
ES2052735T3 (en) 1987-09-18 1994-07-16 R Tech Ueno Ltd A METHOD FOR PRODUCING AN EYE HYPOTENSION AGENT.

Also Published As

Publication number Publication date
GB2216004A (en) 1989-10-04
JP2597629B2 (en) 1997-04-09
ZA891410B (en) 1989-11-29
EP0330511A3 (en) 1989-10-18
AU612791B2 (en) 1991-07-18
KR970005170B1 (en) 1997-04-14
ATE79260T1 (en) 1992-08-15
DE68902401T2 (en) 1992-12-10
KR890012654A (en) 1989-09-18
EP0330511A2 (en) 1989-08-30
OA09236A (en) 1992-06-30
JPH01221317A (en) 1989-09-04
GR3005933T3 (en) 1993-06-07
EP0330511B1 (en) 1992-08-12
DE68902401D1 (en) 1992-09-17
ES2044087T3 (en) 1994-01-01
GB8904232D0 (en) 1989-04-12
CA1314483C (en) 1993-03-16
NZ228111A (en) 1991-02-26

Similar Documents

Publication Publication Date Title
AU3029889A (en) Stabilization of 13,14-dihydro-15-ketoprostaglandins
CA2173703A1 (en) Synergistic stabilizer mixture
EP0595133A3 (en) Prodrugs, their preparation and use as medicaments
SG2295G (en) Metropolol succinate and pharmaceutical composition containing it
AU4740893A (en) Stabilized pharmaceutical compositions containing derivatives of vitamins D2 and D3
AU1071288A (en) Polyolefin stabilising composition
EP0228862A3 (en) Stabilized human tissue plasminogen activator compositions
AU3900189A (en) Stabilized hydrogen peroxide compositions
UA29435C2 (en) 3<font face="Symbol">b</font>-ALKENYLPENAM DERIVATIVES AND PHARMACEUTICALLY COMPATIBLE SALTS THEREOF
IE900709L (en) Pharmaceutical composition which contains a pharmaceutically¹suitable carrier and the compound having the structure¹(7ó,17ó)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-¹3-one
EP0221728A3 (en) Monosaccharide containing wound healing preparation
AU1866888A (en) Pharmaceutical dosage unit containing 17beta-oestradiol and desogestrel
AU3645489A (en) Insecticidaln'-substituted-n-alkylcarbonyl-n'- acylhydrazines and n'-substituted-n-acyl-n'- alkylcarbonylhydrazines
IL105475A0 (en) Pharmaceutical compositions containing 1alpha,24(r)-dihydroxy-22(e)-dehydro-vitamin d3 for treating osteoporosis
ES2004097A6 (en) Tricyclic derivative, namely 5-(3-chloro-6-methyl-5,5-dioxo-6,11-dihydro-dibenzo[C,F] [1,2]-thiazepin-11-ylamino)-pentanoic acid, process for its preparation and medicines and medicines containing it.
HU9202163D0 (en) New glyco-peptides, method for producing them and pharmaceutical preparatives containing these compounds
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
AU2403592A (en) 2-aza-2-desamino analogues of 5,8-dideazafolic acid
AU581694B2 (en) Stabilized of bacampicillin hydrochloride compositions
AU5297693A (en) Stabilized compositions containing 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o-meth yl-oxime
IL75985A (en) 3-(o-chlorophenyl)-3-aminoalkyl-2,5-pyrrolidinedione derivatives
AU639216B2 (en) Pharmaceutically active CNS compounds
AU662224B2 (en) New 7beta-substituted-4-aza-5alpha-androstan-3-ones as 5alpha-reductase inhibitors
AR242777A1 (en) Active insecticide compounds that are derivatives of n,n'-dibenzoylhydrazine and a compound that contains them.

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired